357 Studies Now Enrolling
A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
| Sponsor: | Therapeutic Advances in Childhood Leukemia and Lymphoma TACL |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAU7753 |
| U.S. Govt. ID: | NCT05476770 |
| Contact: | Nobuko Hijiya, MD: 2123059770 / nh2636@cumc.columbia.edu |
Additional Study Information:
This study is for 1 to 21-year-olds whose hematologic cancer has relapsed to take medication called Tagraxofusp. Relapse means that cancer has come back after treatment. Tagraxofusp is a drug approved by the FDA (Food and Drug Administration) but is not approved to treat the cancers of people in this study. This study is being done to find out if Tagraxofusp can be safely given together with other chemotherapy drugs for cancer. About 54 children and young adults will participate in this study.
Do You Qualify?
| Are you or your child between the ages of 1 and 21? | Yes | No |
| Do you have a relapsed and/or refractory hematologic malignancy, or do your tumor cells demonstrate surface expression of CD123? | Yes | No |
| Have you recovered from any acute side effects of previous chemotherapy, immunotherapy, or radiation treatment? | Yes | No |